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tAmong the primary objectives of the American
ociety for Blood and Marrow Transplantation are to:
Deﬁne commonly accepted medical practice
Develop standards of medical care for autologous
and allogeneic transplants
Provide recommendations and guidelines for the
role of transplantation as a therapeutic approach
for reimbursement by third party payers.
o this end, in 1999, the Society began the develop-
ent of evidence-based reviews of the scientiﬁc and
edical literature to document when blood and mar-
ow transplantation is indicated in the treatment of
elected diseases.
oals
The goals of the evidence-based reviews are to:
Determine which diseases will be the subject of
each review, and develop a list of questions to be
addressed
Assemble and critically evaluate all the valid,
peer-reviewed evidence regarding the role of cy-
totoxic therapy with hematopoietic stem cell
transplantation related to the disease
Make treatment recommendations based on the
available evidence
Identify discrepancies in study design or method-
ology among published studies that may have an
impact on the quality of the evidence
Identify needed areas of additional research
uidelines
The following guidelines are offered for the role
f stem cell transplantation (SCT) as therapy for acute
yelogenous leukemia (AML) in children, and are
ased on consensus reached by an expert panel1 fol-
owing an evidence-based review of the literature:2
ransplantation versus Chemotherapy
. Autologous SCT and chemotherapy in the ﬁrst
complete remission are equivalent in outcomes.
The lack of data on quality of life, secondary ma-
lignancies, and other late effects of treatment pre- b
00vent a recommendation of one treatment over the
other.
. Allogeneic SCT shows superior overall survival
(OS) and leukemia-free survival when compared to
chemotherapy for patients in the ﬁrst complete
remission (CR1). Thus, allogeneic SCT is recom-
mended in the ﬁrst complete remission. Additional
prospective data regarding risk subgroups may sub-
sequently alter this recommendation.
. In allogeneic SCT versus chemotherapy in the
second CR, the expert panel acknowledges a lack of
evidence comparing matched related allogeneic do-
nors (MRD) versus chemotherapy. Nonetheless, the
expert panel consensus recommends the use of any
suitable allogeneic MRD if one is available. A
matched unrelated donor (MUD) or other alternative
donor SCT is recommended in the context of a clin-
ical trial.
ransplantation Techniques
. MRD allogeneic SCT has superior survival out-
comes compared to autologous SCT in the CR1.
Additional prospective data regarding risk sub-
Expert panel members and authors of the review are: Denise
liansky, Roswell Park Cancer Institute (RPCI), Buffalo, NY; J.
ouglas Rizzo, Medical College of Wisconsin, Milwaukee, WI;
eter D. Aplan, National Institutes of Health, National Cancer
nstitute, Genetics Branch, Bethesda, MD; Robert J. Arceci, Kimmel
omprehensive Cancer Center, Baltimore, MD; Louis Leone,
hildren’s Oncology Group, Arcadia, CA; Yaddanapudi
avindranath, Children’s Hospital of Michigan and Wayne State
niversity School of Medicine, Detroit, MI; Jean E. Sanders, Fred
utchinson Cancer Research Center, University of Washington,
eattle, WA; Franklin O. Smith III, Cincinnati Children’s Hospital
nd Medical Center and University of Cincinnati College of
edicine, Cincinnati, OH; Fiona Wilmot, Blue Shield of California,
an Francisco, CA; Philip L. McCarthy, Jr., RPCI; Theresa Hahn,
PCI.
Reference: Oliansky D, Rizzo JD, Aplan PT, et al. Role of
ytotoxic therapy with hematopoietic stem cell transplantation in
he therapy of acute myeloid leukemia in children: an evidence-












ASBMT Position Statement 501groups may alter this recommendation. The con-
sensus recommendation of the expert panel is to
use bone marrow as the stem cell source in the
MRD allogeneic SCT setting based on scientiﬁc,
ethical, regulatory, and practical issues.
. In the second CR, the consensus recommendation
is to use any suitable MRD or MUD over autolo-
gous SCT. There is, however, a lack of evidence
that one has better outcomes than the other.
. Although the current practice is to use peripheral
blood SCT (PBSCT), there are very few patients in
the studies that fulﬁlled the inclusion criteria for the
review. A randomized trial of autologous BMT versus
PBSCT is not feasible because of the infrequent use
of autologous SCT for pediatric patients with AML.
. There is a preference for using MUD or other
alternative donors over autologous SCT if an
MRD is not available.
. No effective purging agents are currently available. If
one were available, it would increase interest in a clin-
ical trial of purged versus unpurged autologous SCT.
ndications for SCT
. There are no data to recommend using related
versus unrelated allogeneic SCT. Although there
are differences among institutions with regard to
transplant techniques, there are no apparent differ-
ences in outcomes. T. MRD allogeneic SCT is preferred in the ﬁrst or
second CR. In the second remission, alternative
donors could be considered if MRD is not avail-
able.
. Based on a lack of evidence, no recommendation
can be made for a preferred technique for unrelated
allogeneic SCT (eg, T cell depletion, cord blood
versus PBSCT versus BMT, and so on).
. No difference or preference for one myeloablative
condition regimen over another can be recom-
mended with respect to OS, leukemia-free survival,
or late effects of SCT.
. There is no evidence of a beneﬁt of SCT for acute
promyelocytic leukemia (APL) in the ﬁrst remis-
sion, and it is not recommended.
. For APL in the second complete remission, the
preferred practice is to use allogeneic SCT. Au-
tologous SCT is recommended if there is no
suitable MUD, MRD, or other alternative donor.
An alternative would be a clinical trial comparing
haploidentic allogeneic versus autologous SCT.
Adopted by the ASBMT Executive Committee
on January 18, 2007
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